SCHEMBL6154616

SCHEMBL6154616

COC(=O)CC(CC(=O)OC)C(=O)OCc1cccc(Br)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.52
CYP2D6 P10635 2/20 0.52
CYP2C19 P33261 2/20 0.52
CYP1A2 P05177 1/20 0.52
GLA P06280 1/20 0.51
HCAR2 Q8TDS4 1/20 0.50
MMP1 P03956 1/20 0.47
MMP2 P08253 1/20 0.47
MMP9 P14780 1/20 0.47
MMP12 P39900 1/20 0.47
MAOB P27338 7/20 0.46
PARP15 Q460N3 2/20 0.45
HSP90AA1 P07900 1/20 0.45
IDO1 P14902 2/20 0.44
AGXT P21549 2/20 0.44
MAOA P21397 2/20 0.43
PARP14 Q460N5 1/20 0.43
PARP10 Q53GL7 1/20 0.43
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6154497 0.84 POLB (0.53) MMP2MMP9MMP12MAOBHSP90AA1
SCHEMBL6155887 0.83 KDM4E (0.53) CYP2D6CYP2C19CYP1A2HCAR2MMP1
SCHEMBL6153292 0.83 ALDH1A1 (0.53) CYP3A4HCAR2MMP1MMP2MMP9
SCHEMBL6153180 0.83 NPC1 (0.52) CYP1A2MMP1MMP2MMP9MMP12
SCHEMBL10795647 0.82 HCAR2 (0.55) CYP3A4CYP2D6CYP2C19CYP1A2GLA
SCHEMBL6156492 0.82 KMT2A (0.48) CYP1A2GLAMMP1MAOB
SCHEMBL6156888 0.80 RAB9A (0.56) CYP2D6CYP2C19MAOBMAOACYP2C9
SCHEMBL27342289 0.79 HSP90AA1 (0.60) CYP3A4CYP2D6CYP2C19CYP1A2GLA
SCHEMBL4269762 0.79 CYP1A2 (0.62) CYP3A4CYP2D6CYP2C19CYP1A2GLA
SCHEMBL22624583 0.77 SLC7A5 (0.45) CYP3A4CYP2D6CYP2C19CYP1A2GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050119341-A1 3-substituted oxyglutaric diester compound, optically active 3-substituted oxyglutaric monoester compound, and processes for producing these UBE INDUSTRIES, LTD. (JP) 2005-06-02 US disclosed
EP-1500642-A1 3-SUBSTITUTED OXYGLUTARIC DIESTER COMPOUND, OPTICALLY ACTIVE 3-SUBSTITUTED OXYGLUTARIC MONOESTER COMPOUND, AND PROCESSES FOR PRODUCING THESE Ube Industries, Ltd. (JP) 2005-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119341-A1 3-substituted oxyglutaric diester compound, optically active 3-substituted oxyglutaric monoester compound, and processes for producing these OGDH, GLUL, ADSL CYP3A4 393/4885CYP2D6 420/4885CYP2C19 524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.